NP5 Stock Overview
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Newron Pharmaceuticals S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF7.15 |
| 52 Week High | CHF12.50 |
| 52 Week Low | CHF3.84 |
| Beta | 0.70 |
| 1 Month Change | -8.33% |
| 3 Month Change | -7.74% |
| 1 Year Change | 43.57% |
| 3 Year Change | 225.74% |
| 5 Year Change | -8.63% |
| Change since IPO | -78.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NP5 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -8.5% | -2.9% | -2.5% |
| 1Y | 43.6% | -31.3% | -0.4% |
Return vs Industry: NP5 exceeded the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: NP5 exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| NP5 volatility | |
|---|---|
| NP5 Average Weekly Movement | 12.9% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NP5's share price has been volatile over the past 3 months.
Volatility Over Time: NP5's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 22 | Stefan Weber | www.newron.com |
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication.
Newron Pharmaceuticals S.p.A. Fundamentals Summary
| NP5 fundamental statistics | |
|---|---|
| Market cap | €128.15m |
| Earnings (TTM) | -€16.22m |
| Revenue (TTM) | €9.06m |
14.1x
P/S Ratio-7.9x
P/E RatioIs NP5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NP5 income statement (TTM) | |
|---|---|
| Revenue | €9.06m |
| Cost of Revenue | €0 |
| Gross Profit | €9.06m |
| Other Expenses | €25.28m |
| Earnings | -€16.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 19, 2024
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 100.00% |
| Net Profit Margin | -179.13% |
| Debt/Equity Ratio | -160.6% |
How did NP5 perform over the long term?
See historical performance and comparison